1. European Medicines Agency. Cablivi (caplacizumab): summary of product characteristics. 2018.
http://www.ema.europa.eu
. Accessed 7 Sept 2018.
2. Sanofi. Cablivi™ (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP) [media release].
http://www.news.sanofi.us/
. Accessed 3 Sept 2018.
3. European Medicines Agency. Cablivi (caplacizumab): EU assessment report. 2018.
http://www.ema.europa.eu/ema/
. Accessed 13 Jun 2018.
4. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836–46.
5. Ablynx. Understanding nanobodies. 2018.
http://www.ablynx.com/technology-innovation/understanding-nanobodies/
. Accessed 14 Sept 2018.